Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Notes Payables (2020 - 2021)

Rocket Pharmaceuticals (RCKT) has disclosed Notes Payables for 2 consecutive years, with $5.1 million as the latest value for Q2 2021.

  • Quarterly Notes Payables changed N/A to $5.1 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Jun 2021, changed N/A year-over-year, with the annual reading at $4.9 million for FY2020, N/A changed from the prior year.
  • Notes Payables hit $5.1 million in Q2 2021 for Rocket Pharmaceuticals, up from $5.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $5.1 million in Q2 2021 to a low of $4.8 million in Q3 2020.